A pharmacology primer: Theory, application and methods

A Pharmacology Primer: Theory, Application and Methods

Volumn , Issue , 2009, Pages 1-389

  Kenakin, Terry P ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85133558537     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374585-9.X0001-1     Document Type: Book

References (282)

1. Chen W.-J., Armour S., Way J., Chen G.C., Watson C., Irving P.E., Cobb J., Kadwell S., Beaumont K., Rimele T., Kenakin T.P. Expression cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells and their relationship to amylin receptors. Mol. Pharmacol. 1997, 52:1164-1175.
2. Kenakin T.P., Cook D.A. Blockade of histamine-induced contractions of intestinal smooth muscle by irreversibly acting agents. Can. J. Physiol. Pharmacol. 1976, 54:386-392.
3. Wilson S., Chambers J.K., Park J.E., Ladurner A., Cronk D.W., Chapman C.G., Kallender H., Browne M.J., Murphy G.J., Young P.W. Agonist potency at the cloned human beta-3 adrenoceptor depends on receptor expression level and nature of assay. J. Pharmacol. Exp. Ther. 1996, 279:214-221.
4. Goldberg N.D. Cyclic nucleotides and cell function. Cell membranes, biochemistry, cell biology, and pathology 1975, 185-202. H. P. Publishing, New York. G. Weissman, R. Claiborne (Eds.).
5. Kenakin T.P., Beek D. Is prenalterol (H 133/80) really a selective beta-1 adrenoceptor agonist? Tissue selectivity resulting from differences in stimulus-response relationships. J. Pharmacol. Exp. Ther. 1980, 213:406-413.
6. Kenakin T.P., Ambrose J.R., Irving P.E. The relative efficiency of beta-adrenoceptor coupling to myocardial inotropy and diastolic relaxation: Organ-selective treatment of diastolic dysfunction. J. Pharmacol. Exp. Ther. 1991, 257:1189-1197.
7. Kenakin T.P., Beek D. The measurement of the relative efficacy of agonists by selective potentiation of tissue responses: Studies with isoprenaline and prenalterol in cardiac tissue. J. Auton. Pharmacol. 1984, 4:153-159.
8. Burgen A.S.V., Spero L. The action of acetylcholine and other drugs on the efflux of potassium and rubidium from smooth muscle of the guinea-pig intestine. Br. J. Pharmacol. 1968, 34:99-115.
9. Kenakin T.P. Differences between natural and recombinant G-protein coupled receptor systems with varying receptor G-protein stoichiometry. Trends Pharmacol. Sci. 1997, 18:456-464.
10. Kenakin T.P. Collateral efficacy as pharmacological problem applied to new drug discovery. Expert Opin. Drug Disc. 2006, 1:635-652.
11. Lefkowitz R.J., Shenoy S.K. Transduction of receptor signals by arrestins. Science 2005, 308:512-517.
12. Luttrell L.M. Composition and function of G protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity. J. Mol. Neurosci. 2005, 26:253-263.
13. Azzi M., Charest P.G., Angers S., Rousseau G., Kohout T. arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G-protein-coupled receptors. Proc. Natl. Acad. Sci. USA 2003, 100:11406-11411.
14. 2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol. Pharmacol. 2006, 70:1575-1584.
15. Kenakin T.P. Pharmacological onomastics: What's in a name?. Br. J. Pharmacol. 2008, 153:432-438.
16. 2A receptors by agonists and antagonists. Brain Res. Bulletin 2001, 56:441-451.
17. Paton W.D.M. On becoming a pharmacologist. Ann. Rev. Pharmacol. and Toxicol. 1986, 26:1-22.
18. 1B receptor on CHO cells: Functional responses in the absence of radioligand binding. Br. J. Pharmacol. 1996, 117:1119-1126.
19. Ferrar P., Li C.H. endorphin: Radioreceptor binding assay. Int. J. Pept. Protein Res. 1980, 16:66-69.
20. Maehle A.-H., Prull C.-R., Halliwell R.F. The emergence of the drug-receptor theory. Nature Rev. Drug. Disc. 2002, 1:1637-1642.
21. Paton W.D.M. On becoming a pharmacologist. Ann. Rev. Pharmacol. and Toxicol. 1986, 26:1-22.
22. Drews J. Drug discovery: A historical perspective. Science 2000, 287:1960-1964.
23. Clark A.J. The mode of action of drugs on cells 1933, Edward Arnold, London.
24. Clark A.J. General pharmacology. Handbuch der Experimentellen Pharmakologie 1937, 4:165-176. Springer, Berlin, Ergansungsweerk band. A. Heffter (Ed.).
25. Holmstedt B., Liljestrand G. Readings in pharmacology 1981, Raven Press, New York.
26. Marchese A., George S.R., Kolakowski L.F., Lynch K.R., O'Dowd B.F. Novel GPCR's and their endogenous ligands: Expanding the boundaries of physiology and pharmacology. Trends Pharmacol. Sci. 1999, 20:370-375.
27. Venter J.C., et al. The sequence of the human genome. Science 2001, 291:1304-1351.
28. 2-C10 homolog responsible for an interspecies variation in antagonist binding. Mol. Pharmacol. 1992, 42:16-17.
29. Black J.W. A personal view of pharmacology. Ann. Rev. Pharmacol. Toxicol. 1996, 36:1-33.
30. Buscher R., Hermann V., Insel P.A. Human adrenoceptor polymorphisms: Evolving recognition of clinical importance. Trends Pharmacol. Sci. 1999, 20:94-99.
31. Stephenson R.P. A modification of receptor theory. Br. J. Pharmacol. 1956, 11:379-393.
32. Norton S. Origins of pharmacology. Mol. Interventions 2005, 5:144-149.
33. Leff P., Martin G.R., Morse J.M. Differences in agonist dissociation constant estimates for 5-HT at 5-HT2-receptors: a problem of acute desensitization?. Br. J. Pharmacol. 1986, 89:493-499.
34. Linderstrom-Lang A., Schellman P. Protein conformation. Enzymes 1959, 1:443-471.
35. Burgen A.S.V. Conformational changes and drug action. Fed. Proc. 1966, 40:2723-2728.
36. Wyman J.J., Allen D.W. The problem of the haem interaction in haemoglobin and the basis for the Bohr effect. J. Polymer Sci. 1951, 7:499-518.
37. Del Castillo J., Katz B. Interaction at end-plate receptors between different choline derivatives. Proc. Roy. Soc. Lond. B. 1957, 146:369-381.
38. Freire E. Can allosteric regulation be predicted from structure?. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:11680-11682.
39. Clark A.J. The mode of action of drugs on cells 1933, Edward Arnold, London.
40. Costa T., Herz A. Antagonists with negative intrinsic activity at opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:7321-7325.
41. Samama P., Cotecchia S., Costa T., Lefkowitz R.J. A mutation-induced activated state of the 2-adrenergic receptor: Extending the ternary complex model. J. Biol. Chem. 1993, 268:4625-4636.
42. Clark A.J. General pharmacology. Handbuch der Experimentellen Pharmakologie 1937, 4:165-176. Springer, Berlin, Ergansungsweerk band. A. Heffter (Ed.).
43. Stephenson R.P. A modification of receptor theory. Br. J. Pharmacol. 1956, 11:379-393.
44. Ariens E.J. Affinity and intrinsic activity in the theory of competitive inhibition. Arch. Int. Pharmacodyn. Ther. 1954, 99:32-49.
45. Ariens E.J. Molecular pharmacology 1964, Academic Press, New York, Vol. 1.
46. MacKay D. A critical survey of receptor theories of drug action. Kinetics of drug action 1977, 255-322. Springer-Verlag, Berlin. J.M. Van Rossum (Ed.).
47. Furchgott R.F. The use of haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Advances in drug research 1966, 21-55. Academic Press, New York. N.J. Harper, A.B. Simmonds (Eds.).
48. Furchgott R.F. The classification of adrenoreceptors (adrenergic receptors): An evaluation from the standpoint of receptor theory. Handbook of experimental pharmacology, catecholamines 1972, Vol. 33:283-335. Springer-Verlag, Berlin. H. Blaschko, E. Muscholl (Eds.).
49. Black J.W., Leff P. Operational models of pharmacological agonist. Proc. R. Soc. Lond. [Biol.] 1983, 220:141.
50. Cuatrecasas P. Membrane receptors. Ann. Rev. Biochem. 1974, 43:169-214.
51. DeLean A., Stadel J.M., Lefkowitz R.J. A ternary complex model explains the agonist-specific binding properties of adenylate cyclase coupled adrenergic receptor. J. Biol. Chem. 1980, 255:7108-7117.
52. Kenakin T.P. The pharmacologic consequences of modeling synoptic receptor systems. Biomedical applications of computer modeling 2000, 1-20. CRC Press, Boca Raton. A. Christopoulos (Ed.).
53. Del Castillo J., Katz B. Interaction at end-plate receptors between different choline derivatives. Proc. R. Soc. London, B. 1957, 146:369-381.
54. Monod J., Wyman J., Changeux J.P. On the nature of allosteric transition. J. Mol. Biol. 1965, 12:306-329.
55. Colquhoun D. The relationship between classical and cooperative models for drug action. A symposium on drug receptors 1973, 149-182. University Park Press, Baltimore. H.P. Rang (Ed.).
56. Karlin A. On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine. J. Theoret. Biol. 1967, 16:306-320.
57. Thron C.D. On the analysis of pharmacological experiments in terms of an allosteric receptor model. Mol. Pharmacol. 1973, 9:1-9.
58. Hulme E.C., Birdsall N.J.M., Burgen A.S.V., Metha P. The binding of antagonists to brain muscarinic receptors. Mol. Pharmacol. 1978, 14:737-750.
59. Lefkowitz R.J., Mullikin D., Caron M.G. Regulation of adrenergic receptors by guanyl-5-yl imidodiphosphate and other purine nucleotides. J. Biol. Chem. 1976, 251:4686-4692.
60. MaGuire M.E., Van Arsdale P.M., Gilman A.G. An agonist-specific effect of guanine nucleotides on the binding of the beta adrenergic receptor. Mol. Pharmacol. 1976, 12:335-339.
61. Weiss J.M., Morgan P.H., Lutz M.W., Kenakin T.P. The cubic ternary complex receptor-occupancy model. J. Theroet. Biol. 1996, 178:151-167.
62. Weiss J.M., Morgan P.H., Lutz M.W., Kenakin T.P. The cubic ternary complex receptor-occupancy model. J. Theroet. Biol. 1996, 178:169-182.
63. Weiss J.M., Morgan P.H., Lutz M.W., Kenakin T.P. The cubic ternary complex receptor-occupancy model. J. Theoret. Biol. 1996, 181:381-397.
64. Chen G., Way J., Armour S., Watson C., Queen K., Jayawrickreme C., Chen W.-J., Kenakin T.P. Use of constitutive G-protein-coupled receptor activity for drug discovery. Mol. Pharmacol. 1999, 57:125-134.
65. Bouaboula M., Perrachon S., Milligan L., Canatt X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.-P., Le Fur G., Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor. J. Biol. Chem. 1997, 272:22330-22339.
66. Onaran H.O., Costa T. Agonist efficacy and allosteric models of receptor action. Ann. N. Y. Acad. Sci. 1997, 812:98-115.
67. Onaran H.O., Scheer A., Cotecchia S., Costa T. A look at receptor efficacy. The pharmacology of functional, biochemical, and recombinant systems handbook of experimental pharmacology 2000, Vol. 148:217-280. Springer, Heidelberg. T.P. Kenakin, J.A. Angus (Eds.).
68. Kenakin T.P. Collateral efficacy as pharmacological problem applied to new drug discovery. Expert Opin. Drug Disc. 2006, 1:635-652.
69. Hulme E.C. Receptor biochemistry: A practical approach 1990, Oxford University Press, Oxford.
70. Klotz I.M. Ligand-receptor energetics: A guide for the perplexed 1997, John Wiley and Sons, New York.
71. Limbird L.E. Cell surface receptors: A short course on theory and methods 1995, Martinus Nihjoff, Boston.
72. Chen W.-J., Armour S., Way J., Chen G., Watson C., Irving P., Cobb J., Kadwell S., Beaumont K., Rimele T., Kenakin T.P. Expression cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells and their relationship to amylin receptors. Mol. Pharmacol. 1997, 52:1164-1175.
73. Cheng Y.C., Prusoff W.H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
74. Sabroe I., Peck M.J., Van Keulen B.J., Jorritsma A., Simmons G., Clapham P.R., Williams T.J., Pease J.E. A small molecule antagonist of chemokine receptors CCR1 and CCR3. J. Biol. Chem. 2000, 275:25985-25992.
75. Hejnova L., Tucek S., El-Fakahany E.E. Positive and negative allosteric interactions on muscarinic receptors. Eur. J. Pharmacol. 1995, 291:427-430.
76. Jakubic J., El-Fakahany E.E. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 1997, 52:172-177.
77. Jakubic J., Bacakova L., El-Fakahany E.E., Tucek S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 1997, 52:172-179.
78. Proska J., Tucek S. Mechanisms of steric and cooperative interactions of alcuronium on cardiac muscarinic acetylcholine receptors. Mol. Pharmacol. 1994, 45:709-717.
79. Christopoulos A. Quantification of allosteric interactions at G-protein coupled receptors using radioligand assays. Current protocol in pharmacology 2000, 1.22.21-1.22.40. Wiley and Sons, New York. S.J. Enna (Ed.).
80. Lazareno S., Birdsall N.J.M. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: Interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 1995, 48:362-378.
81. 2A-adrenergic receptor. Mol. Pharmacol. 1998, 53:916-925.
82. o in reconstituted phospholipid vesicles. J. Biol. Chem. 1989, 264:3909-3915.
83. 1 MF-2 smooth muscle cells. Mol. Pharmacol. 1990, 38:660-666.
84. Lefkowitz R.J., Caron M.G., Michel T., Stadel J.M. Mechanisms of hormone-effector coupling: The adrenergic receptor and adenylate cyclase. Fed. Proc. 1982, 41:2664-2670.
85. Motulsky H.J., Mahan L.C. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol. Pharmacol. 1984, 25:1-9.
86. Ehlert F.J. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol. Pharmacol. 1985, 28:410-421.
87. Chio C.L., Lajiness M.E., Huff R.M. Activation of heterologously expressed D3 dopamine receptors: Comparison with D2 dopamine receptors. Mol. Pharmacol 1994, 45:51-60.
88. Roettger B.F., Ghanekar D., Rao R., Toledo C., Yingling J., Pinon D., Miller L.J. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol. Pharmacol 1997, 51:357-362.
89. Adie E.J., Kalinka S., Smith L., Francis M.J., Marenghi A., Cooper M.E., Briggs M., Michael N.P., Milligan G., Game S. A pH-sensitive fluor CypHer 5, used to monitor agonist-induced G-protein coupled receptor internalization in live cells. Biotechniques 2002, 33:1152-1157.
90. Chen G., Way J., Armour S., Watson C., Queen K., Jayawrickreme C., Chen W.-J., Kenakin T.P. Use of constitutive G protein-coupled receptor activity for drug discovery. Mol. Pharmacol 1999, 57:125-134.
91. 2-adrenergic receptors in rat C6 glioma cells: Functional interactions between closely related subtypes. Mol. Pharmacol 1996, 50:175-184.
92. 16 couple a wide variety of receptors to phospholipase C. J. Biol. Chem 1995, 270:15175-15180.
93. Johnson M.P., Wisnoski D.D., Leister W.H., O'Brien J.A., Lemaire W., Williams D.L., Burno M., Sur C., Kinney G.G., Pettibone D.J., Tiller P.R., Smith S., Duggan M.E., Hartman G.D., Conn P.J., Huff J.R. Discovery of the positive allosteric modulators of the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1-H-pyrazol-5-yl)benzamides that potentiate receptor function. J. Med. Chem 2004, 47:5825-5828.
94. Kenakin T.P. Differences between natural and recombinant G-protein coupled receptor systems with varying receptor/G-protein stoichiometry. Trends Pharmacol. Sci 1997, 18:456-464.
95. Barlow R.B., Scott K.A., Stephenson R.P. An attempt to study the effects of chemical structure on the affinity and efficacy of compounds related to acetylcholine. Br. J. Pharmacol 1967, 21:509-522.
96. Kenakin T.P., Cook D.A. N,N-Diethyl-2-(1-pyridyl)ethylamine, a partial agonist for the histamine receptor in guinea pig ileum. Can. J. Physiol. Pharmacol 1980, 58:1307-1310.
97. Furchgott R.F. The use of haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Advances in drug research 1966, Vol. 3:21-55. Academic Press, London, New York. N.J. Harper, A.B. Simmonds (Eds.).
98. Kenakin T.P. The pharmacologic analysis of drug receptor interaction 1997, Lippincott-Raven, New York. 3rd ed.
99. Kenakin T.P. The relative contribution of affinity and efficacy to agonist activity: Organ selectivity of noradrenaline and oxymetazoline. Br. J. Pharmacol 1984, 81:131-141.
100. Paton W.D.M., Rang H.P. The uptake of atropine and related drugs by intestinal smooth muscle of the guinea pig in relation to acetylcholine receptors. Proc. R. Soc. Lond. [Biol.] 1965, 163:1-44.
101. Gaddum J.H. The quantitative effects of antagonistic drugs. J. Physiol. Lond. 1937, 89:7P-9P.
102. Gaddum J.H., Hameed K.A., Hathway D.E., Stephens F.F. Quantitative studies of antagonists for 5-hydroxytryptamine. Q. J. Exp. Physiol. 1955, 40:49-74.
103. Arunlakshana O., Schild H.O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959, 14:48-58.
104. Kenakin T.P., Boselli C. Pharmacologic discrimination between receptor heterogeneity and allosteric interaction: Resultant analysis of gallamine and pirenzeipine antagonism of muscarinic responses in rat trachea. J. Pharmacol. Exp. Ther. 1989, 250:944-952.
105. Kenakin T.P. The Schild regression in the process of receptor classification. Can. J. Physiol. Pharmacol. 1982, 60:249-265.
106. Stephenson R.P. A modification of receptor theory. Br. J. Pharmacol. 1956, 11:379-393.
107. Kaumann A.J., Marano M. On equilibrium dissociation constants for complexes of drug receptor subtypes: Selective and nonselective interactions of partial agonists with two adrenoceptor subtypes mediating positive chronotropic effects of isoprenaline in kitten atria. Naunyn Schmiedebeberg's Arch. Pharmacol. 1982, 219:216-221.
108. Kenakin T.P., Black J.W. The pharmacological classification of practolol and choropractolol. Mol. Pharmacol. 1978, 14:607-623.
109. 2 values and associated analysis. J. Pharmacol. Exp. Ther. 1978, 207:705-718.
110. Lew M.J., Angus J.A. Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol. Sci. 1996, 16:328-337.
111. Black J.W., Leff P., Shankley N.P., Wood J. An operational model of pharmacological agonism: The effect of E/[A] curve shape on agonist dissociation constant estimation. Br. J. Pharmacol. 1985, 84:561-571.
112. Leff P., Dougall I.G., Harper D. Estimation of partial agonist affinity by interaction with a full agonist: A direct operational model-fit approach. Br. J. Pharmacol. 1993, 110:239-244.
113. Jakubic J, Bacakova I, El-Fakahany E.E, Tucek S Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol 1997, 52:172-179.
114. Koshland D.E. The active site of enzyme action. Adv. Enzymol 1960, 22:45-97.
115. Lee N.H., Hu J., El-Fakahany E.E. Modulation by certain conserved aspartate residues of the allosteric interaction of gallamine and the ml muscarinic receptor. J. Pharmacol. Exp. Ther 1992, 262:312-316.
116. Smerdon S.J., Jager J., Wang J., Kohlstaedt L.A., Chirino A.J., Friedman J.M., Rice P.A., Steitz T.A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 1994, 91:3911-3915.
117. Horn J.R, Shoichet B.K. Allosteric inhibition through core disruption. J. Mol. Biol 2004, 336:1283-1291.
118. Oikonomakos N.G., Skamnaki V.T., Tsitsanou K.E., Gavalas N.G., Johnson L. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure 2000, 8:575-584.
119. Arkin M.R., Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nature Rev. Drug Disc 2004, 3:301-317.
120. Teague S.J. Implications of protein flexibility for drug discovery. Nature Reviews Drug Discovery 2003, 2:527-541.
121. Watson C., Jenkinson S., Kazmierski W., Kenakin T.P. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric non-competitive HIV entry-inhibitor. Mol. Pharmacol 2005, 67:1268-1282.
122. Tong C., Churchill L, Cirillo P.F., Gilmore T, Graham A.G., Grob P.M., Hickey E.R., Moss N., Pav S., Regan F. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nature Sturctural Mol. Biol. 2002, 9:268-272.
123. Bieniassz P.D., Fridell R.A., Aramori I., Ferguson S.S., Caron M.G., Cullen B.R. HIV-1 induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J 1997, 16:2599-2609.
124. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendricks W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
125. Doranz B.J, Lu Z.-H, Rucker J, Zhang T.-Y, Sharron M, Cen Y.-H, Wang Z.-X, Guo H.-H, Du J.-D, Accavitti M.A, Doms R.W, Peiper S.C Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J. Virol 1997, 71:6305-6314.
126. Poignard P., Saphire E.O., Parren P.W., Burton D.R. gp120: Biologic aspects of structural features. Annu. Rev. Immunol 2001, 19:253-274.
127. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
128. Trkola A., Kuhmann S.E., Strizki J.M., Maxwell E., Ketas T., Morgan T., Pugach P., Xu S., Wojcik L., Tagat J., Palani A., Shapiro S., Clader J.W., McCombie S., Reyes G.R., Baroudy B.M., Moore J.P. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. USA 2002, 99:395-400.
129. Korber B.T., Wolinsky S.M., Moore J.P., Kuhmann S.E, Pugach P, Kunstman K.J, Taylor J, Stanfield R.L, Snyder A, Strizki J.M, Riley J, Baroudy B.M, Wilson I.A, et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from small-molecule CCR inhibitor. J. Virol 2004, 78:2790-2807.
130. Nagasaw T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996, 382:635-638.
131. Tachibana K., Hirota S., Iizasa H., Yoshida H., Kawabata K., Kataoka Y., Kitamura Y., Matsushima K., Yoshida N., Nishikawa S., Kishimoto T., Nagasawa T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998, 393:591-594.
132. Zou Y.R., Kottmann A.H., Kuroda M., Taniuchi I., Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.
133. Sachpatzidis A., Benton B.K., Manfredis J.P., Wang H., Hamilton A., Dohlman H.G., Lolis E. Indentification of allosteric peptide agonists of CXCR4. J. Biol. Chem 2003, 278:896-907.
134. Heveker N., Montes M., Germeroth L., Amara A., Trautmann A., Alizon M., Schneider-Mergener J. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides. Current Biology 1998, 8:369-376.
135. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-417.
136. Tucek S., Proska J. Allosteric modulation of muscarinic acetylcholine receptors. Trends Pharmacol. Sci 1995, 16:205-212.
137. Flicker L. Acetylcholinesterase inhibitors for Alzheimer's disease. Br. Med. J 1999, 318:615-616.
138. Maelicke A, Albuquerque E.X New approach to drug therapy of Alzheimer's dementia. Drug Discovery Today 1996, 1:53-59.
139. Krause R.M, Buisson B, Bertrand S, Corringer P.-J, Galzi J.-L, Changeux J.-P, Bertrand D Ivermectin: A positive allosteric effector of the a7 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol 1998, 53:283-294.
140. Ehlert F.J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol 1988, 33:187-194.
141. Black J.W., Leff P., Shankley N.P., Wood J. An operational model of pharmacological agonism: The effect of E/[A] curve shape on agonist dissociation constant estimation. Br. J. Pharmacol 1985, 84:561-571.
142. Kenakin T.P. New concepts in durg discovery: Collateral efficacy and permissive antagonism. Nature Rev. Durg Disc 2005, 4:919-927.
143. Kenakin T.P., Jenkinson S., Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J. Pharmacol. Exp. Ther 2006, 319:710-723.
144. Price M.R., Baillie G.L., Thomas A., Stevenson L.A., Easson M., Goodwin R., McLean A., Mclntosh L., Goodwin G., Walker G., Westwood P., Marrs J., Thomson F., Cowley P., Chistopoulos A., Pertwee R.G., Ross R.A. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharm 2005, 68:1484-1495.
145. Christopoulos A. Overview of receptor allosterism. Current protocols in pharmacology 2000, Vol 1:1.21.21-1.21.45. John Wiley and Sons, New York.
146. Gaddum J.H., Hameed K.A., Hathway D.E., Stephens F.F. Quantitative studies of antagonists for 5-hydroxytryptamine. Q. J. Exp. Physiol 1955, 40:49-74.
147. Jakubic J., Bacakova L., Lisá V., El-Fakahany E.E., Tucek S. Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc. Natl. Acad. Sci. USA 1996, 93:8705-8709.
148. Lipinski C., Lombardo F., Dominy B., Feeney P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 2001, 23:3-25.
149. Richardson B.P., Engel G., Donatsch P., Stadler P.A. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985, 316:126-131.
150. Baldwin J.J., Lumma W.C., Lundell G.F., Ponticello G.S., Raab A.W., Engelhardt E.L., Hirschmann E.L., Sweet C.S., Scriabine A. Symbiotic approach to drug design: Antihypertensive adrenergic blocking agents. J. Med. Chem. 1979, 22:1284-1290.
151. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Tox. Meth. 2000, 44:235-249.
152. Jakubic J., Bacakova I., El-Fakahany E.E., Tucek S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 1997, 52:172-179.
153. Finke P.E., Oates B., Mills S.G., MacCoss M., Malkowitz L., Springer M.S., Gould S.L., DeMartino J.A., Carella A., Carver G., et al. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-Activity relationships for 1-[N-(Methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 2001, 11:2475-2479.
154. Zhang J.-H., Chung T.D.Y., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomeolecular Screening 1999, 4:67-72.
155. Andrews P.R., Craik D.J., Martin J.L. Functional group contributions to drug-receptor interactions. J. Med. Chem. 1984, 27:1648-1657.
156. Hopkins A.L., Groom C.R., Alex A. Ligand efficiency: A useful metric for lead selection. Drug Disc. Today 2004, 9:430-431.
157. Kuntz I.D., Chen K., Sharp K.A., Kollman P.A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. USA 1999, 96:9997-10002.
158. Roettger B.F., Ghanekar D., Rao R., Toledo C., Yingling J., Pinon D., Miller L.J. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol. Pharmacol. 1997, 51:357-362.
159. Pommier Y., Cherfils J. Interfacial inhibition of macromolecular interactions: Nature's paradigm for drug discovery. Trend. Pharmacol. Sci. 2005, 26:138-145.
160. Onaran H.O., Costa T. Agonist efficacy and allosteric models of receptor action. Ann. N. Y. Acad. Sci. 1997, 812:98-115.
161. Onaran H.O., Scheer A., Cotecchia S., Costa T. A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor. The pharmacology of functional, biochemical, and recombinant systems handbook of experimental pharmacology 2000, 217-280. Springer, Heidelberg, Vol. 148. T.P. Kenakin, J.A. Angus (Eds.).
162. Kenakin T.P., Onaran O. The ligand paradox between affinity and efficacy: Can you be there and not make a difference?. Trends Pharmacol. Sci. 2002, 23:275-280.
163. Marullo S., Bouvier M. Resonance energy transfer approaches in molecular pharmacology and beyond. Trends Pharmacol. Sci. 2007, 28:362-365.
164. Hoffmann C., Gaietta G., Bünemann M., Adams S., Oberdorff-Maass S., Behr B., et al. A FLASH-based approach to determine G protein-coupled receptor activation in living cells. Nat. Methods 2005, 2:171-176.
165. Azzi M., Charest P.G., Angers S., Rousseau G., Kohout T. arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G-protein-coupled receptors. Proc. Natl. Acad. Sci. USA 2003, 100:11406-11411.
166. Julious S.A. Using confidence intervals around individual means to assess statistical significance between two means. Pharmaceut. Stat. 2004, 3:217-222.
167. Manas E.S., Unwalla R.J., Xu Z.B., Malamas M.S., Miller C.P., Harris H.A., Hsiao C., Akopian T., Hum W.-T., Malakian K., Wolfrom S., Bapat A., Bhat R.A., Stahl M.L., Somers M.S., Alvarez J.C. Structure-based design of estrogen receptor-selective ligands. J. Amer. Chem. Soc. 2004, 126:15106-15119.
168. Tang Z., Taylor M.J., Lisboa P., Dyas M. Quantitative risk modeling for new pharmaceutical compounds. Drug Disc. Today 2005, 22:1520-1526.
169. Teague S.J., Davis A.M., Leeson P.D., Oprea T.J. The design of leadlike combinatorial libraries. Angewandte Chemie International Edition 1999, 38:3743-3748.
170. King F.D., Brown A.M., Gaster L.M., Kaumann A.J., Medhurst A.D., Parker S.G., Parsons A.A., Patch T.L., Raval P. (.+-.)-3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: A conformationally restricted analog of 5-carboxamidotryptamine with selectivity for the serotonin 5-HT1D receptor. J. Med. Chem. 1993, 36:1918.
171. Yanagisawa T., Wakabayashi S., Tomiyama T., Yasunami M., Takase K. Synthesis and anti-ulcer activities of sodium alkylazulene sulfonates. Chem. Pharm. Bull. 1988, 36:641.
172. Giudici D., Ornati G., Briatico G., Buzzetti F., Lombardi P., di Salle E. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): A new irreversible aromatase inhibitor. J. Steroid. Biochem. 1988, 30:391.
173. Bhat B., Seth M., Bhaduri A.P. Indian J. Chem. 1981, 20B:703.
174. Krapcho J., Turk C., Cushman D.W., Powell J.R., DeForrest J.M., Spitzmiller E.R., Karanewsky D.S., Duggan M., Rovnyak G., Schwartz J., Natarajan S., Godfrey J.D., Ryono D.E., Neubeck R., Atwal K.S., Petrillo E.W. Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines. J. Med. Chem. 1988, 31:1148.
175. Sham H.L., Kempf D.J., Molla A., Marsh K.C., Kumar G.N., Chen C.-M., Kati W., Stewart K., Lal R., Hsu A., Betebenner D., Korneyeva M., Vasavanonda S., McDonald E., Saldivar A., Wideburg N., Chen X., Niu P., Park C., Jayanti V., Grabowski B., Granneman G.R., Sun E., Japour A.J., Leonard J.M., Plattner J.J., Norbeck D.W. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 1998, 42:3218.
176. Proudfoot J.R. Drugs, leads, and drug-likeness: An analysis of some recently launched drugs. Bioogan. Med. Chem. Lett. 2002, 12:1647-1650.
177. Shargel L., Yu A.B.C., Wu-Pong S. Applied biopharmaceutics and pharmacokinetics 2004, 510. McGraw-Hill, New York.
178. Whitebread S., Hamon J., Bojanic D., Urban L. In vitro safety pharmacology profiling: An essential tool for successful drug development. Drug Disc. Today 2005, 10:1421-1433.
179. Silvetre J.S., Prous J. Research on adverse drug events: Muscarinic m3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Meth. Find. Exp. Clin. Pharmacol. 2005, 27:289-304.
180. Wienkers L.C., Heath T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nature Rev. Drug Discovery 2005, 4:825-833.
181. Klabunde T., Evers A. GPCR antitarget modeling: Pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effect. Chem. Bio. Chem. 2005, 6:876-889.
182. Kazius J., Bursi R. Derivation and validation of toxicophores for mutagenicity prediction. J. Med. Chem. 2005, 48:312-320.
183. Aguiar A.J., Krc J., Kinkel A.W., Samyn A.C. Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate. J. Pharm. Sci. 1967, 56(7):847-853.
184. Schanker L.S., Tocco D.T., Brodie B.B., Hogben C.A.M. Absorption of drugs from the rat small intestine. J. Pharmacol. Exp. Ther. 1958, 123:81-88.
185. Lemke T.L. Review of organic functional groups: Introduction to medicinal organic chemistry 1992, Lea and Febiger, Philadelphia. 3rd ed.
186. Cates I.A. Calculation of drug solubilities by pharmacy students. Amer. J. Pharm. Ed. 1981, 45:11-13.
187. Williams D.A., Lemke T.L. Foye's principle of medicinal chemistry 2002, Lippincott, Williams, Wilkins, New York. 5.
188. Navia M.A., Chaturvedi P.R. Design principles for orally bioavailable drugs. Drug Disc. Today 1996, 1:179-199.
189. Kerns E.H., Di L., Petusky S., Farris M., Ley R., Jupp P. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J. Pharm. Sci. 2004, 93:1440-1453.
190. Balimane P.V., Chong S. Cell culture-based models of intestinal permeability: A critique. Drug. Disc. Today 2005, 10:335-343.
191. Soars M.G., McGinnity D.F., Grime K., Riley R.J. The pivotal role of hepatocytes in drug discovery. Chemico-Biol. Interactions 2007, 168:2-15.
192. Gomez-Lechon M., Castell J.V., Donato M.T. Hepatocytes-the choice to investigate drug metabolism and toxicity in man: In vitro variability as a reflection of in vivo. Chemico-Biol. Interactions 2007, 168:30-50.
193. Galloway J.A., McMahon R.E., Culp H.W., Marshall F., Young E.C. Metabolism, blood levels and rate of excretion of acetohexamide in human subjects. Diabetes 1965, 16:118-127.
194. Izumi T., Enomoto S., Hosiyama K., Sasahara K., Shibukawa A., Nakagawa T., Suguyama Y. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J. Pharmacol. Exp. Ther. 1996, 277:1630-1641.
195. Siefert H.M., Domdey-Bette A., Henninger K., Hucke F., Kohlsdorfer C., Stass H.H. Pharmacokinetics of 8-methoxyquinoloe, moxifloxacin: A comparison in humans and other mammalian species. J. Antimicrob. Chemother. 1999, 43(Suppl. B):69-76.
196. van de Waterbeemd H., Gifford E. ADMET in silico modeling: Towards prediction paradise?. Nature Rev. Drug Disc. 2003, 2:192-204.
197. Booth B., Zemmel R. Prospects for productivity. Nature Rev. Drug Disc. 2004, 3:451-456.
198. Williams M. A return to the fundamentals of drug discovery. Curr. Opin. Investigational Drugs 2004, 5:29-33.
199. Walker M.J.A., Barrett T., Guppy L.J. Functional pharmacology: The drug discovery bottleneck?. Drug Disc. Today 2004, 3:208-215.
200. Spedding M., Jay T., Cost de Silva J., Perret L. A pathophysiological paradigm for the therapy of psychiatric disease. Nature Rev. Drug. Disc. 2005, 4:467-476.
201. Hopkins A.L., Groom C.R. The druggable genome. Nature Rev. Drug Disc. 2002, 1:727-730.
202. Claverie J.-M. What if there were only 30,000 human genes?. Science 2001, 291:1255-1257.
203. Drews J. Drug discovery: A historical perspective. Science 2000, 287:1960-1964.
204. Luster A.D. Mechanisms of disease: Chemokines-Chemotactic cytokines that mediate inflammation. N. Eng. J. Med. 1998, 338:436-445.
205. Zaitseva M., Blauvelt A., Lee S., Lapham C.K., Klaus-Kovtun V., Mostowski H., Manischewitz J., Golding H. Expression and function of CCR5 and CXCR4 on human langerhans cells and macrophages: Implications for HIV primary infection. Nature Medicine 1997, 3:1369-1375.
206. Cagnon L., Rossi J.J. Downregulation of the CCRS beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. Antisense & Nucleic Acid Drug Development 2000, 10:251-261.
207. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 1999, 96:5698-5703.
208. + T cells. Science 1995, 270:1811-1815.
209. Finke P.E., Oates B., Mills S.G., MacCoss M., Malkowitz L., Springer M.S., Gould S.L., DeMartino J.A., Carella A., Carver G., et al. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure: Activity relationships for 1-[N-(Methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 2001, 11:2475-2479.
210. Mack M., Luckow B., Nelson P.J., Cihak J., Simmons G., Clapham P.R., Signoret N., Marsh M., Stangassinger M., Borlat F., Wells T.N.C., Schlondorff D., Proudfoot A.E.I. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 1998, 187:1215-1224.
211. Simmons G., Clapham P.R., Picard L., Offord R.E., Rosenkilde M.M., Schwartz T.W., Buser R., Wells T.N.C., Proudfoot A.E.I. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997, 276:276-279.
212. Garzino-Demo A., Moss R.B., Margolick J.B., Cleghorn F., Sill A., Blattner W.A., Cocchi F., Carlo D.J., DeVico A.L., Gallo R.C. Spontaneous and antigen-induced production of HIV-inhibitory-chemokines are associated with AIDS-free status. Proc. Natl. Acad. Sci. USA 1999, 96:11986-11991.
213. Ullum H., Lepri A.C., Victor J., Aladdin H., Phillips A.N., Gerstoft J., Skinhoj P., Klarlund Pedersen B.K. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: Evidence that high levels of macrophage in inflammatory protein-1-beta are associated with a decreased risk of HIV progression. J. Infect. Dis. 1998, 177:331-336.
214. Grivel J.-C., Ito Y., Faga G., Santoro F., Shaheen F., Malnati M.S., Fitzgerald W., Lusso P., Margolis L. Suppression of CCR5-but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nature Med. 2001, 7:1232.
215. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., Goedert J.J., Buchbinder S.P., Vittinghoff E., Gomperts E., Donfield S., Vlahov D., Kaslow R., Saah A., Rinaldo C., Detels R. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996, 273:1856-1862.
216. Huang Y., Paxton W.A., Wolinsky S.M., Neumann A.U., Zhang L., He T., Kang S., Ceradini D., Jin Z., Yazdanbakhsh K., Kunstman K., Erickson D., Dragon E., Landau N.R., Phair J., Ho D.D., Koup R.A. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med. 1996, 2:1240-1243.
217. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.I., Stuhlmann H., Koup R.A., Landau N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
218. Paxton W.A., Martin S.R., Tse D., O'Brien T.R., Skurnick J., VanDevanter N.L., Padian N., Braun J.F., Kotler D.P., Wolinsky S.M., Koup R.A. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nature Med. 1996, 2:412-417.
219. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumerouilie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Collman R.G., Doms R.W., Vassart G., Parmentier M. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles to the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
220. Cook D.N., Beck M.A., Coffman T.M., Kirby S.L., Sheridan J.F., Pragnell I.B., Smithies O. Requirement of MIP-1 for an inflammatory response to viral infection. Science 1995, 269:1583-1585.
221. Knudsen T.B., Kristiansen T.B., Katsenstein T.L., Eugen-Olsen J. Adverse effect of the CCR5 promoter -2459A allele on HIV-1 disease progression. J. Med. Virol. 2001, 65:441.
222. Neubig R.R., Siderovski D.P. Regulators of G-protein signaling as new central nervous system drug targets. Nature Rev. Drug Disc. 2002, 1:187-196.
223. Mestas J., Hughes C.C. Of mice and not men: Differences between mouse and human immunology. J. Immunol. 2004, 172:2731-2738.
224. Hill R. NK1 (Substance P) receptor antagonists: Why are they not analgesic in humans?. Trends Pharmacol. Sci. 2000, 21:244-246.
225. Strizki J.M., Xu S., Wagner N.E., Wojcik L., Liu J., Hou Y., Endres M., Palani A., Shapiro S., Clader J.W., et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2001, 98:12718-12723.
226. 2-adrenoceptor gene polymorphisms. Pharmacogenet. Genom. 2005, 15:267-275.
227. Kost T.A., Condreay J.P. Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends Biotechnol. 2002, 20:173-180.
228. Douglas S.A., Ohlstein E.H., Johns D.G. Techniques: Cardiovascular pharmacology and drug discovery in the 21st century. Trends Pharmacol. Sci. 2004, 25:225-233.
229. Heldin C.H. Dimerization of cell surface receptors in signal transduction. Cell 1995, 80:213-223.
230. George S.R., O'Dowd B.F., Lee S.P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nature Rev. Drug Disc. 2002, 1:808-820.
231. AbdAlla S., Lother H., Quitterer U. At1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 2000, 407:94-98.
232. AbdAla S., Lother H., el Massiery A., Quitterer U. Increased AT(1) receptor dimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nature Med. 2001, 7:1003-1009.
233. Mellado M., Rodríguez-Frade J.M., Vila-Coro A.J., Fernández S., Martín de Ana A., Jones D.R., Torán J.L., Martínez-Aet C. Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J. 2001, 20:2497-2507.
234. Wildoer M., Fong J., Jones R.M., Lunzer M.M., Sharma S.K., Kostensis E., Portoghese P.S., Whistler J.L. A heterodimer-selective agonist shows in vivo relevance of G-protein coupled receptor dimers. Proc. Nat. Acad. Sci. USA 2005, 102:9050-9055.
235. Milligan G., Ramsay D., Pascal G., Carrillo J.J. GPCR dimerization. Life Sci. 2003, 74:181-188.
236. Kubinyi H. Drug research: Myths, hype, and reality. Nature Rev. Drug Disc. 2003, 2:665-668.
237. Armour S.L., Foord S., Kenakin T., Chen W.-J. Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor. J. Pharmacol. Toxicol. Meth. 1999, 42:217-224.
238. Foord S.M., Marshall F.H. RAMPS: Accessory proteins for seven transmembrane domain receptors. Trends Pharmacol. Sci. 1999, 20:184-187.
239. Fraser N.J., Wise A., Brown J., McLatchie L.M., Main M.J., Foord S.M. The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin-like receptor. Mol. Pharmacol. 1999, 55:1054-1059.
240. Kunkel E.J., Dea M., Ebens A., Hytopoulos E., Melrose J., Nguyen D., Ota K.S., Plavec I., Wang Y., Watson S.R., Butcher E.C., Berg E.L. An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB J. 2004, 18:1279-1301.
241. Kunkel E.J., Plavec I., Nguyen D., Melrose J., Rosler E.S., Kao L.T., Wang Y., Hytopoulos E., Bishop A.C., Bateman R., Shokat K.M., Butcher E.C., Berg E.L. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMap analysis in complex human primary cell-based models. ASSAY Drug. Dev. Technol. 2004, 2:431-441.
242. Siegel P.M., Massague J. Cytostatic and apoptotic actions of TGF in homeostasis and cancer. Nature Rev. Cancer 2003, 3:807-821.
243. Dage R.C., Roebel L.E., Hsieh C.P., Weiner D.L., Woodward J.K. The effects of MDL 17,043 on cardiac inotropy in the anaesthetized dog. J. Cardiovasc. Pharmacol. 1982, 4:500-512.
244. Kenakin T.P., Scott D.L. A method to assess concomitant cardiac phosphodiesterase inhibition and positive inotropy. J. Cardiovasc. Pharmacol. 1987, 10:658-666.
245. Kenakin T.P., Pike N.B. An in vivo analysis of purine-mediated renal vasoconstriction in rat isolated kidney. Br. J. Pharmacol. 1987, 90:373-381.
246. Kenakin T.P. Drug and organ selectivity: Similarities and differences. Advances in drug research 1985, Vol. 15:71-109. Academic Press, New York.
247. Littman B.H., Williams S.A. The ultimate model organism: Progress in experimental medicine. Nature Rev. Drug Disc. 2005, 4:631-638.
248. 4) antagonist in patients with active rheumatoid arthritis (RA). Arthritis Rheum. 2004, 50::S239.
249. Tarazi F.I., Zhang K., Baldessarini R.J. Review: Dopamine D4 receptors: Beyond schizophrenia. J. Recept. Sig. Transduct. Res. 2004, 24:131-147.
250. Milne G.M. Pharmaceutical productivity: The imperative for new paradigms. Annu. Rep. Med. Chem. 2003, 38:383-396.
251. Sikora K. Surrogate endpoints in cancer drug development. Drug Disc. Today 2002, 7:951-956.
252. Baczko I., El-Reyani N.E., Farkas A., Virág L., Iost N., Leprán I., Mátyus P., Varró A., Papp J.G. Antiarrhythmic and electrophysiological effects of GYK-16638, a novel N-(phenoxyalkyl)-N-phenylalkylamine, in rabbits. Eur. J. Pharmacol. 2000, 404:181-190.
253. Morphy R., Rankovic Z. Designed multiple ligands: An emerging drug discovery paradigm. J. Med. Chem. 2005, 48:6523-6543.
254. Perez M., Pauwels P.J., Fourrier C., Chopin P., Valentin J.-P., John G.W., Marien M., Halazy S. Dimerization of sumitryptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist. Bioorg. Med. Chem. Lett. 1998, 8:675-680.
255. 1 opioid receptor phenotypes. J. Med. Chem. 2005, 48:1713-1716.
256. Zhang M., van de Stolpe A., Zuiderveld O., Timmermans H. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Eur. J. Med. Chem. 1997, 32:95-102.
257. Kenakin T.P., Johnson S.F. The importance of adrenoceptor agonist activity of dobutamine to inotropic selectivity in the anaesthetized cat. Eur. J. Pharmacol. 1985, 111:347-354.
258. Metra M., Dei Cas L., di Lenarda A., Poole-Wilson P. Beta-blockers in heart failure: Are pharmacological differences clinically important?. Heart Fail. Rev. 2004, 9:123-130.
259. Black J.W., Leff P. Operational models of pharmacological agonist. Proc. R. Soc. Lond. [Biol.] 1983, 220:141.
260. Stephenson R.P. A modification of receptor theory. Br. J. Pharmacol. 1956, 11:379-393.
261. Kenakin T.P. The pharmacologic analysis of drug receptor interaction 1997, 1-491. Lippincott-Raven, New York. 3rd ed.
262. Kenakin T.P., Beek D. Is prenalterol (H 133/80) really a selective beta-1 adrenoceptor agonist? Tissue selectivity resulting from difference in stimulus-response relationships. J. Pharmacol. Exp. Ther.. 1980, 213:406-413.
263. Kenakin T.P. Allosteric agonist modulators. J. Recept. Signal. Transd. 2007, 27:247-259.
264. Cheng Y.C., Prusoff W.H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
265. Leff P., Dougall I.G. Further concerns over Cheng-Prusoff analysis. Trends Pharmacol. Sci. 1993, 14:110-112.
266. Kenakin T.P. Collateral efficacy in drug discovery: Taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol. Sci.. 2007, 28:407-415.
267. Kew J.N.C., Trube G., Kemp J.A. A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurons. J. Physiol. 1996, 497:761-772.
268. Copeland R.A., Pompliano D.L., Meek T.D. Drug target residence time and its implications for lead optimization. Nat. Rev. Drug Disc. 2006, 5::730-739.
269. Kenakin T.P., Jenkinson S., Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J. Pharmacol. Exp. Ther. 2006, 319:710-723.
270. Gaddum J.H. The quantitative effects of antagonistic drugs. J. Physiol. Lond. 1937, 89:7P-9P.
271. Boeynaems J.M., Dumont J.E. Outlines of receptor theory 1980, Elsevier/North-Holland, Amsterdam.
272. Non-linear models: SAS system recognition 1991, SAS Institute, Cary, North Carolina. R.J. Freund, C.R. Litell (Eds.).
273. Giraldo J., Vivas N.M., Vila E., Badia A. Assessing the (a)symmetry of concentration-effect curves: Empirical versus mechanistic models. Pharmacol. Therap 2002, 95:21-45.
274. Gobel J., Saussy D.L., Goetiz A.S. Development of scintillation-proximity assays for alpha adrenoceptors. J. Pharmacol. Toxicol. Meth 1999, 42:2-7.
275. Gompertz B. On the nature of the function expressive of the law of human mortality. Philo. Trans. R. Soc. Lond 1825, 36:513-585.
276. Kenakin T.P., Beek D. The measurement of antagonist potency and the importance of selective inhibition of agonist uptake processes. J. Pharmacol. Exp. Ther 1981, 219:112-120.
277. Richards F.J. A flexible growth function for empirical use. J. Exp. Bot 1959, 10:290-300.
278. Van Der Graaf P.H., Schoemaker R.C. Analysis of asymmetry of agonist concentration-response curves. J. Pharmacol. Toxicol. Meth 1999, 41:107-115.
279. Watson C., Chen G., Irving P.E., Way J., Chen W.-J., Kenakin T.P. The use of stimulus-biased assay systems to detect agonist-specific receptor active states: Implications for the trafficking of receptor stimulus by agonists. Mol. Pharmacol 2000, 58:1230-1238.
280. Cheng Y.C., Prusoff W.H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
281. Kenakin T.P., Beek D. Self-cancellation of drug properties as a mode of organ selectivity: The antimuscarinic effects of ambenonium. J. Pharmacol. Exp. Ther. 1985, 232:732-740.
282. Jakubic J., Bacakova L., Lisa V., El-Fakahany E.E., Tucek S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 1997, 52:172-179.